Therapeutic response and side effects of repeated radioligand therapy with (177)Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Por Ahmadzadehfar, Hojjat, Eppard, Elisabeth, Kürpig, Stefan, Fimmers, Rolf, Yordanova, Anna, Schlenkhoff, Carl Diedrich, Gärtner, Florian, Rogenhofer, Sebastian, Essler, Markus
Publicado no Oncotarget (2016)

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Por Ahmadzadehfar, Hojjat, Rahbar, Kambiz, Kürpig, Stefan, Bögemann, Martin, Claesener, Michael, Eppard, Elisabeth, Gärtner, Florian, Rogenhofer, Sebastian, Schäfers, Michael, Essler, Markus
Publicado no EJNMMI Res (2015)

Theranostics in nuclear medicine practice

Por Yordanova, Anna, Eppard, Elisabeth, Kürpig, Stefan, Bundschuh, Ralph A, Schönberger, Stefan, Gonzalez-Carmona, Maria, Feldmann, Georg, Ahmadzadehfar, Hojjat, Essler, Markus
Publicado no Onco Targets Ther (2017)

Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride

Por Ahmadzadehfar, Hojjat, Zimbelmann, Stefanie, Yordanova, Anna, Fimmers, Rolf, Kürpig, Stefan, Eppard, Elisabeth, Gaertner, Florian C., Wei, Xiao, Hauser, Stefan, Essler, Markus
Publicado no Oncotarget (2017)

Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer

Por Gaertner, Florian C., Halabi, Khalil, Ahmadzadehfar, Hojjat, Kürpig, Stefan, Eppard, Elisabeth, Kotsikopoulos, Charalambos, Liakos, Nikolaos, Bundschuh, Ralph A., Strunk, Holger, Essler, Markus
Publicado no Oncotarget (2017)

Theranostics

Publicado em 2021

Advances in Dosimetry and New Trends in Radiopharmaceuticals

Publicado em 2024